1. Home
  2. CCD vs DRTS Comparison

CCD vs DRTS Comparison

Compare CCD & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Dynamic Convertible & Income Fund

CCD

Calamos Dynamic Convertible & Income Fund

HOLD

Current Price

$24.54

Market Cap

662.0M

Sector

Finance

ML Signal

HOLD

Logo Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd.

HOLD

Current Price

$7.52

Market Cap

641.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCD
DRTS
Founded
2014
2015
Country
United States
Israel
Employees
N/A
121
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
662.0M
641.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CCD
DRTS
Price
$24.54
$7.52
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
106.8K
330.6K
Earning Date
01-01-0001
05-18-2026
Dividend Yield
10.61%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$699.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.17
$2.59
52 Week High
$24.66
$8.80

Technical Indicators

Market Signals
Indicator
CCD
DRTS
Relative Strength Index (RSI) 68.07 48.11
Support Level $20.20 $6.47
Resistance Level $24.64 $7.75
Average True Range (ATR) 0.46 0.56
MACD 0.03 -0.02
Stochastic Oscillator 83.50 19.00

Price Performance

Historical Comparison
CCD
DRTS

About CCD Calamos Dynamic Convertible & Income Fund

Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

Share on Social Networks: